- Optimi Health is set to open its new psilocybin cultivation facility in British Columbia
- The facility is the largest GMP-grade psilocybin cultivation facility in Canada
- The Vancouver-based company was awarded a dealer’s license in February by Health Canada
- The company has started growing its inaugural crop at the 10,000 square foot facility
- Optimi Health is up 1.69 percent, trading at $0.30 at 2:38 p.m. ET
Optimi Health (OPTI) is set to open its new psilocybin cultivation facility in British Columbia.
The facility is the largest GMP-grade psilocybin cultivation facility in Canada.
The Vancouver-based company was awarded a dealer’s license in February by Health Canada. Since that time, the company has been focused on securing supply deals and letters of intent with pharmaceutical companies, other licensed suppliers, and drug developers.
The facility will open to the public and for tours on May 27.
Optimi’s operational footprint includes a 10,000-square foot facility devoted to the production of natural GMP psilocybin for use by approved entities in clinical trials and individuals granted access by Health Canada through legal mechanisms such as the Special Access Program and Section 56 exemptions to the Controlled Drugs and Substances Act.
The company recently announced that it had commenced growing its first crop of natural psilocybin for these purposes.
“Psychedelics continue to capture the imagination of people looking for hope and better quality of life, specifically those suffering with debilitating mental health conditions,” said Optimi Health CEO Bill Ciprick.
“By having the largest GMP-grade Health Canada licensed mushroom cultivation facility in Canada, we have positioned Optimi to be the number one supplier of safe, natural psilocybin, and we feel good about setting the safest and most stringent production standards in the industry.”
Optimi Health is up 1.69 percent, trading at $0.30 at 2:38 p.m. ET.
